title: The FDA black box for EPO: what should nephrologists do?
authors.affiliation: Renal Division, Brigham and Women's Hospital, Boston, USA.
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Singh
mesh_terms: D000740:Anemia / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions; D004921:Erythropoietin / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives; D006397:Hematinics / Q000008:administration & dosage* / Q000009:adverse effects; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D017410:Practice Guidelines as Topic; D006435:Renal Dialysis; D014481:United States
chemical_list: D006397:Hematinics; D006454:Hemoglobins; D004921:Erythropoietin